![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
DB104 (liafensine) is a first–in–class triple reuptake inhibitor targeting transporters for serotonin, norepinephrine, and dopamine. It is being evaluated for the treatment of patients with treatment-resistant depression.
Lead Product(s): Liafensine
Therapeutic Area: Psychiatry/Psychology Product Name: DB104
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.
Lead Product(s): Liafensine
Therapeutic Area: Psychiatry/Psychology Product Name: DB104
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Curia
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022